Hear From Key Stakeholders: The Future Treatment and Access Landscape for Cell & Gene Therapies Roundtable
The first negotiated prices of the Inflation Reduction Act (IRA) will not apply until 2026. The numerous shifts in cost-sharing responsibility that collectively constitute Medicare Part D Benefit Redesign will not begin until 2024 and will take full effect in 2025. And as early as 2023, pharmaceutical manufacturers and payers will have to contend with one of the more imminent potential impacts of the law: inflationary rebates for Medicare utilization. Learn more about the impact and nuances of the IRA on prescription drug pricing from Precision’s Kyle Sarnataro.
